Heqet

Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results

Retrieved on: 
수요일, 4월 10, 2024
FDA, Drug discovery, Synovitis, Cell, Research, Vaccine, IND, Nanoparticle, Allergic rhinitis, DNMT3B, Dicarboxylic acid, Inflammation, Hearing loss, Osteoarthritis, Vertigo, RNA, Myocardial infarction, Patent, CHF, Messenger, Betahistine, Therapy, Semaphore, AVS, Dizziness, AAV, Tinnitus, Heqet, Rhinitis, Central nervous system, Clinical trial, Small RNA, Sale, Cancer, EDT, Liver, Patient, Rheumatoid arthritis, Histamine, Regeneration

HAMILTON, BERMUDA -- April 10, 2024 -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today provided a business update and reported its full year 2023 financial results.

Key Points: 
  • "Altamira emerged from the 2023 business year as a stronger and more focused company," commented Thomas Meyer, Altamira Therapeutics' founder, Chairman, and CEO.
  • "We keep progressing with our RNA delivery business, concluding recently our second collaboration agreement with another exciting biotech company.
  • Altamira expects to make further progress in 2024 with the strategic repositioning by partnering its inner ear therapeutics assets.
  • Altamira’s Senior Management will hold an investor call today, Wednesday, April 10, 2024, at 8:30 a.m. EDT to discuss its business update and full-year 2023 results.

Ethris and Heqet Therapeutics Announce Collaboration to Develop RNA-based Therapeutics for Heart Attack and Heart Failure

Retrieved on: 
월요일, 11월 13, 2023
Snap, Therapy, Small RNA, Regeneration, Tissue, Biotechnology, Vaccination, Patient, Myocardial infarction, Regenerative medicine, Vaccine, Heqet, Heart failure, Inhalation, LNP, Cardiac muscle, Death, Cell, RNA, Pharmaceutical industry

Under the terms of the agreement, Heqet Therapeutics will lead the development of the program, while Ethris will provide its proprietary Stabilized NanoParticle (SNaP) LNP platform to deliver ncRNA payloads to the heart tissue.

Key Points: 
  • Under the terms of the agreement, Heqet Therapeutics will lead the development of the program, while Ethris will provide its proprietary Stabilized NanoParticle (SNaP) LNP platform to deliver ncRNA payloads to the heart tissue.
  • "Our RNA delivery platform was designed to deliver any type of RNA payload to a broad range of tissues," said Dr. Carsten Rudolph, CEO of Ethris.
  • Under the terms of the collaboration agreement, Ethris and Heqet will operate under a comprehensive commercial agreement, which encompasses various milestone and royalty payments.
  • By harnessing Ethris' SNaP LNP platform for precise delivery, Heqet aims to test the efficacy of its ncRNA candidates to stimulate cardiac regeneration in patients with myocardial infarction and heart failure.

Altamira Therapeutics Provides Business Update and First Half 2023 Financial Results

Retrieved on: 
화요일, 9월 12, 2023
KRAS, Nanoparticle, Rhinitis, Marketing, Synovitis, Heqet, Allergic rhinitis, RNA, MBA, Doctor of Philosophy, Preprint, Patent, Patient, NF-κB, MITES, AVS, DNMT3B, Rheumatoid arthritis, Joint capsule, Therapy, Myocardial infarction, Research, Small RNA, Regeneration, Sneeze, Washington University School of Law, Neoplasm, Nasal spray, FDA, Vertigo, IND, Safety, Volunteering, SAR, Altamira, Cell, IP, Immunotherapy, Messenger, NASAR, Nasal congestion, CHF, Osteoarthritis Research Society International, Rhinorrhea, Q&A, SARS-CoV-2, Infection, Clinical trial, Pollen, Inflammation, ANCOVA, OTC, Mouse, Washington University School of Medicine, Vaccine, Pharmaceutical industry, Cryptocurrency, BPPV, St. Louis

Company hosts 1H 2023 Financial Results and Business Update call today at 8 a.m.

Key Points: 
  • Company hosts 1H 2023 Financial Results and Business Update call today at 8 a.m.
  • ET
    Altamira Therapeutics Ltd. (NASDAQ:CYTO) ("Altamira" or the "Company"), a company dedicated to addressing unmet medical needs, today provided a business update and reported its first half 2023 financial results.
  • Net loss for the first half of 2023 was CHF 5.4 million compared with CHF 8.2 million for the first half of 2022.
  • ET to discuss its business update and first half 2023 results.

Altamira Therapeutics Announces Collaboration with Heqet Therapeutics on Nanoparticle-Delivered Non-Coding RNAs for Cardiac Regeneration

Retrieved on: 
수요일, 7월 5, 2023
Heart failure, Moyamoya disease, Heart, Nanoparticle, Myocardial infarction, Therapy, Small RNA, Necrosis, American Heart Association, Head, Heqet, Altamira, RNA, Cardiac muscle, King's College London, Imperial College London, Regeneration, Ischemia, MD, Patient, School, Liver, Mortality, Science, Facial muscles, Pharmaceutical industry, Vaccine

Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced that it has entered into a collaboration and option agreement with Heqet Therapeutics s.r.l.

Key Points: 
  • Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced that it has entered into a collaboration and option agreement with Heqet Therapeutics s.r.l.
  • Based in Turin, Italy, Heqet is a biotech spin-out from King’s College London.
  • Under the terms of the agreement, Heqet will test nanoparticles based on Altamira’s OligoPhore delivery platform and comprising certain non-coding RNAs (ncRNAs) in the regeneration of damaged heart tissue following myocardial infarction in animal models.
  • We believe that our peptide-based OligoPhore platform for RNA delivery has the potential to serve as a safe and effective vehicle for engineering controlled local cardiac regeneration.”